PI4K

Other PI3K/Akt/mTOR Inhibitors

PI3K mTOR Akt GSK-3 DNA-PK ATM/ATR PDK AMPK PTEN MELK

Cat.No.	Product Name	Information	Product Use Citations
S1489	PIK-93	PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM; this compound is shown to inhibit PI3Kα with IC50 of 39 nM.	Cell Res, 2025, 10.1038/s41422-025-01085-9 Cell Rep, 2025, 44(5):115634 Sci Rep, 2025, 15(1):28778
S0041	UCB9608	UCB9608 (compound 44) is a potent, selective and orally bioavailable inhibitor of PI4KIIIβ with IC50 of 11 nM. This compound is a potent immunosuppressive agent that improves metabolic stability and exhibits excellent pharmacokinetic profile.
E2981	PI4KIIIbeta-IN-10	PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 of 3.6 nM. It also exhibits weak inhibition of PI3KC2γ, PI3Kα, and PI4KIIIα, and <20% inhibition at concentrations up to 20 µM for PI4K2α, PI4K2β, and PI3Kβ.
S6571	BQR695	BQR695 (NVP-BQR695) is a quinoxaline that displays sub-micromolar potency against human PI4KIIIβ (IC50~90 nM).
S6574	KDU691	KDU691 is a Plasmodium PI4K-specific inhibitor with IC50 values of 0.18 μM and 0.061 μM against hypnozoite forms and liver schizontsm, respectively.
E2374	PI-273	PI-273, the first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM, can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis.
S2728	AG-1478	AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. This compound inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase III (PI4KA).	Cell Death Dis, 2025, 16(1):479 J Stroke Cerebrovasc Dis, 2025, 34(6):108315 Biomed Pharmacother, 2024, 180:117523